



October 26, 2020  
JCR Pharmaceuticals Co., Ltd.

Translation

### Notice of Sales structure Changes for Midterm Business Plan “REVOLUTION”


JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that it will establish new marketing organization and rename departments as part of the sales structure for the midterm business plan “REVOLUTION”, as follows.

In the field of lysosomal storage disorders (LSDs), the launch of our new therapeutics is expected in the future. In this field, JCR will establish the Lysosomal Storage Disorder Group within the Marketing Dept. from November 1, 2020. The Lysosomal Storage Disorder Group will be made up of full-time LSD staff, and will function as an organization that demonstrates a high degree of professional expertise.

Moreover, from December 1, 2020, in the growth hormone business, which remains JCR’s core business, JCR will rename the Sales Operations Dept. as the Sales Promotion Dept. JCR will also newly establish the Growth Hormone Promotion Group. This group will be responsible for promoting the growth hormone business, in order to expand marketing activities based on area market strategies tailored to each area. In addition, JCR will be rename the Kinki-Hokuriku Sales Dept. as the Kinki Sales Dept. in conjunction with the reorganization of five sales Dept. (12 areas) involved in the growth hormone business into five sales Dept. (10areas) to strengthen sales management capabilities.

JCR will allocate resources effectively based on an awareness of the key priorities of its marketing strategies. By doing so, JCR will conduct information delivery and collection activities suited to the needs of medical professionals in each medical field, with the aim of strengthening organizational capabilities and establishing a solid sales platform.

#### <Sales Division (excerpt) >



**[About JCR Pharmaceuticals]**

JCR is a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, "Contributing towards people's healthcare through pharmaceutical products" drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.

**[Cautionary Statement Regarding Forward-Looking Statements]**

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.*

*Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jcrpharm.co.jp](mailto:ir-info@jcrpharm.co.jp)

END

###

